title: Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation.
abstract: OBJECTIVE
  To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  A total of 27 consecutive patients with persistent macular edema resistant to standard short-term therapy despite quiescent noninfectious intermediate or posterior uveitis.
  
  
  METHODS
  Each patient was treated with a DEX 0.7 mg implant.
  
  
  METHODS
  Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection.
  
  
  RESULTS
  A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation.
  
  
  CONCLUSIONS
  The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events.
authors.affiliation: Department of Ophthalmology, School of Medicine, University of Colorado, Aurora, Colorado.
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Cao
authors.affiliation: Colorado Biostatistics Consortium, School of Public Health, University of Colorado, Aurora, Colorado.
authors.forename: Matthew
authors.initials: M
authors.lastname: Mulvahill
authors.affiliation: Colorado Biostatistics Consortium, School of Public Health, University of Colorado, Aurora, Colorado.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Colorado Retina Associates, P.C., Denver, Colorado.
authors.forename: Brian C
authors.initials: BC
authors.lastname: Joondeph
authors.affiliation: Department of Ophthalmology, School of Medicine, University of Colorado, Aurora, Colorado; Colorado Retina Associates, P.C., Denver, Colorado. Electronic address: mdacey@retinacolorado.com.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Dacey
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D002648:Child; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014605:Uveitis / Q000150:complications*; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D004343:Drug Implants; D003907:Dexamethasone